

Comparison of three methods for susceptibility testing of *Mycobacterium avium* subsp. *paratuberculosis* to 11 antimicrobial drugs

Manju Y. Krishnan, Elizabeth J. B. Manning and Michael T. Collins*

Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin–Madison, 2015 Linden Drive, Madison, WI 53706-110, USA

Received 28 January 2009; returned 3 March 2009; revised 24 March 2009; accepted 27 April 2009

Objectives: To evaluate the BACTEC™ MGIT™ 960/MGIT Para TB (MGIT) system for drug susceptibility testing of *Mycobacterium avium* subsp. *paratuberculosis* (MAP), a pathogen implicated in some forms of Crohn's disease.

Methods: MICs of 11 drugs for 10 MAP strains were determined using the MGIT system, the BACTEC™460TB system (BACTEC) and conventional agar dilution methods.

Results: MICs determined by MGIT methods showed 80%–100% agreement ($\pm 1 \log_2$ dilution) with those determined by the BACTEC and agar dilution methods for ciprofloxacin, levofloxacin, azithromycin and clofazimine. The MGIT and BACTEC methods showed 70%, 80% and 90% agreement ($\pm 1 \log_2$ dilution) for MICs of ethambutol, rifabutin and rifampicin; agreement for all drugs increased to 100% at 2 \log_2 dilution differences. For clarithromycin, the MGIT method had greater agreement with the agar dilution method (70% at the same dilution) than the BACTEC method (60% at $\pm 1 \log_2$ dilution); agreement increased to 100% at $\pm 2 \log_2$ dilutions in both cases. The MGIT and agar dilution methods agreed 60% and 100% for amikacin MICs at $\pm 1 \log_2$ dilution and $\pm 2 \log_2$ dilutions, respectively. By all methods MICs were higher than achievable serum concentrations for isoniazid and dapsone. There was 100% agreement between all three methods for azithromycin, clarithromycin and ciprofloxacin, and 80% agreement for rifampicin using published MIC thresholds available for *M. avium* complex strains.

Conclusions: This study shows that the MGIT system can be used for rapid and reliable drug susceptibility testing of MAP.

Keywords: agar dilution, BACTEC, MGIT, MIC

Introduction

Mycobacterium avium subsp. *paratuberculosis* (MAP) causes Johne's disease (paratuberculosis), a chronic inflammatory bowel disease in ruminants. In recent years there have been several reports suggesting an association between MAP and Crohn's disease (CD), a chronic granulomatous inflammatory bowel disease in humans.^{1–5}

The idea that MAP may contribute to some cases of CD is not new. Previous attempts (1982–94) to test this theory involved the treatment of CD patients with anti-tubercular drugs assumed to be efficacious against MAP.⁶ Failure to observe significant clinical improvement dampened enthusiasm for the mycobacterial aetiology theory. Only later was it recognized that MAP is resistant to most first-line tuberculosis (TB) drugs.⁷

More recent clinical trials have treated CD patients with combinations of macrolides, rifabutin and clofazimine based on limited MAP antibiotic susceptibility data and on the assumption that MAP should be similar in susceptibility to other members of the *M. avium* complex (MAC).^{8–14} Clinical outcomes of these studies were generally encouraging, but far from conclusive.^{15,16}

In vitro drug susceptibility data specific for human clinical isolates of MAP are needed to better guide clinical trials targeting MAP in CD patients. However, at present there are no standard methods available for drug susceptibility testing of MAP. The few such studies available used a radiometric [BACTEC™ 460 TB (BACTEC); Becton Dickinson, Sparks, MD, USA] broth dilution method,^{17–20} which is an accurate and reliable macrodilution method for susceptibility testing of MAC.²¹

*Corresponding author. Tel: +1-608-262-8457; Fax: +1-608-265-6463; E-mail: mcollin5@wisc.edu

In clinical laboratories the radiometric system has largely been replaced with the new fully automated BACTEC™ MGIT (mycobacterial growth indicator tube) 960 system (MGIT) (Becton Dickinson) for the isolation^{22,23} and susceptibility testing of pathogenic mycobacteria.^{24,25} The MGIT system was optimized for detection of MAP with a MAP-specific culture medium, MGIT™ ParaTB medium, and has been successfully used for faster and sensitive isolation of MAP from clinical samples and also for quantification of MAP.²⁶ We previously described drug stability in the MGIT™ ParaTB medium²⁷ and *in vitro* susceptibility of MAP to thiopurine drugs.²⁸ In the present study, the MGIT 960 system–MGIT™ ParaTB medium was evaluated for susceptibility testing of MAP strains to different classes of drugs and the results were compared with those of radiometric (BACTEC) and agar dilution methods.

Materials and methods

MAP isolates

Ten clinical isolates of MAP (nine of human origin and one of bovine origin) were used (Table 1). The strains were verified as MAP by detecting IS900 by PCR. All strains were grown in Middlebrook 7H9 broth containing 10% oleic acid–albumin–dextrose–catalase (OADC) supplement (Becton Dickinson) and 2 µg/mL mycobactin J (Allied Monitor, Fayette, MO, USA). Cultures (6–8 weeks old) were harvested, resuspended in fresh Middlebrook 7H9 medium–glycerol (20% final concentration) and transferred to screw-capped test tubes containing 8–10 glass beads (3 mm). Tubes were vigorously vortexed, and allowed to stand for 30 min. The supernatant was stored as aliquots at –80°C until used.

M. avium controls

Strains 101 and 104 were gifts from Dr Venkata Reddy (Sequella Inc., Rockville, MD, USA). Colonies from Middlebrook 7H10 agar plates were inoculated into Middlebrook 7H9 broth containing 10% OADC.

Preparation of inocula

Prior to susceptibility testing, the frozen MAP were inoculated into 4 mL of fresh Middlebrook 7H9 medium and incubated at 37°C for

2–3 days. The turbidity of the culture was adjusted with Middlebrook 7H9 broth to be equivalent to that of a No. 1 McFarland standard (for agar dilution method) or a 0.5 McFarland standard (for MGIT and radiometric methods) using a spectrophotometer (Biomate 3; Thermo Fisher Scientific, Waltham, MA, USA). Cultures (8–10 days old) of *M. avium* 101 and 104 strains were adjusted to a turbidity equivalent to that of a 0.5 McFarland standard.

Drugs

Ciprofloxacin, levofloxacin, azithromycin, clarithromycin, amikacin, ethambutol, clofazimine, isoniazid and dapsone were purchased from Sigma-Aldrich (St Louis, MO, USA). Rifampicin and rifabutin were purchased from USP (Rockville, MD, USA).

Stock solutions of drugs were prepared using the most appropriate solvent: water (amikacin, ethambutol and isoniazid), 0.1 N sodium hydroxide (ciprofloxacin and levofloxacin), methanol (rifampicin and rifabutin), ethanol (azithromycin and clarithromycin) or methanol acidified by trace amounts of glacial acetic acid (clofazimine). The stock solutions were filter-sterilized, if required, and stored at –80°C for up to 2 months.

Prior to testing, each drug was freshly diluted in sterile deionized water. Each drug was tested at a suitable concentration range based on reported C_{max} values. Broadly, ciprofloxacin, levofloxacin, azithromycin, clarithromycin, rifabutin and isoniazid were tested at doubling dilutions in the range 32–0.125 mg/L. Amikacin was tested in the range 25–0.78 mg/L. Rifampicin was tested in the range 12–0.094 mg/L. Ethambutol, clofazimine and dapsone were tested in the range 20–0.156 mg/L.

Susceptibility testing by the MGIT method

The method was adapted from those for *Mycobacterium tuberculosis* and *M. avium* and described earlier for MAP.²⁸ Briefly, the final MGIT™ ParaTB medium was prepared according to manufacturer's instructions by adding 0.8 mL MGIT™ ParaTB supplement and 0.5 mL 50% egg yolk (Becton Dickinson) to 7 mL of MGIT™ ParaTB medium. Clofazimine and amikacin were tested in the absence of egg yolk since the MICs were found to be affected by egg yolk. Each tube received 0.1 mL of inoculum (bacterial suspension with a turbidity equivalent to that of a 0.5 McFarland standard) and 0.1 mL of drug. This inoculum resulted in cfu between 5×10^4 and 5×10^5 /mL, as shown by plate counts. Growth control tubes

Table 1. MAP strains used in the study

| Strain ID | Isolation source |
|----------------------|---|
| ATCC 43015 (Linda) | human, Crohn's disease patient—ileum |
| ATCC 43544 (Ben) | human, Crohn's disease patient—intestinal tissue |
| ATCC 43545 (Dominic) | human, Crohn's disease patient—intestinal tissue |
| ATCC 49164 (Holland) | human, Crohn's disease patient—intestinal tissue |
| UCF3 | human, Crohn's disease patient—ileum, UCF ^a |
| UCF4 | human, Crohn's disease patient—ileum, UCF ^a |
| UCF5 | human, Crohn's disease patient—ileum, UCF ^a |
| UCF7 | human, Crohn's disease patient—ileum, UCF ^a |
| UCF8 | human, Crohn's disease patient—ileum, UCF ^a |
| JTC 303 | bovine, clinical case of paratuberculosis, JTC ^b |

^aGift from Saleh Naser, University of Central Florida, Orlando, FL, USA.

^bIsolated at the Johne's Testing Centre, Madison, WI, USA.

Drug susceptibility testing of *M. paratuberculosis*

received 0.1 mL of sterile water instead of drug. The 1:100 growth control tubes received 1/100 of the standard inoculum. Tubes were incubated in the MGIT™ 960 instrument (Becton Dickinson) and time to detect (TTD) data were recorded. An experiment was considered valid only when the undiluted growth control tube became signal-positive between 2.5 and 4.5 days of incubation and the 1:100 inoculum control tube signalled positive between 7 and 10 days. MIC was defined as the lowest concentration of drug resulting in a TTD value greater than that of the 1:100 growth controls.

Susceptibility testing by the BACTEC method

The BACTEC™ 12B medium (Becton Dickinson) was modified to permit MAP growth, by adding 1 mL of 50% egg yolk suspension (Becton Dickinson) and 0.1 mL of mycobactin J (80 µg/mL) to each vial. Egg yolk was omitted for testing clofazimine. The medium was alkalized while testing azithromycin by adding 0.3 mL of 3% tri-potassium phosphate.²⁹ Drug dilutions were added in volumes of 0.1 mL. Drug-containing and growth control vials received 0.1 mL of MAP suspension equivalent in turbidity to that of a 0.5 McFarland standard, as recommended by the manufacturer for susceptibility testing of *M. tuberculosis*. The 1:100 growth control vials received 0.1 mL of a 100-fold dilution of the same MAP suspension. All vials were incubated at 37°C. Growth index (GI) readings were obtained using a BACTEC™ 460 TB instrument (Becton Dickinson). The 1:100 control vials were read on alternate days until the GI was ≥ 30 (considered positive MAP growth above background³⁰) at which time all drug-containing vials were read that same day and again the following day. Differences in GI between consecutive days (Δ GI) were calculated for each culture. The MIC was defined as the lowest concentration of drug showing both a Δ GI and absolute GI lower than those of the 1:100 growth control.³¹

Susceptibility testing by the agar dilution method

Methods recommended by the CLSI (formerly the NCCLS) for *M. tuberculosis* and slow-growing mycobacteria were used with

minor modifications.²⁹ Drug dilutions were placed in volumes of 0.1 mL at the centre of quadrant Petri plates and overlaid by molten, cooled, Middlebrook 7H10 agar (supplemented with OADC and mycobactin J). Plates were swirled gently to allow mixing of drug with the medium before solidification of agar. An inoculum suspension equivalent in turbidity to that of a No. 1 McFarland standard was diluted to 10^{-2} and 10^{-4} . Drug-containing and control quadrants were inoculated with 0.1 mL of the 10^{-2} dilution while the 1:100 control (1% control) quadrants received 0.1 mL of the 10^{-4} dilution. Plates were sealed and incubated at 37°C for 4–5 weeks.

Data analysis

Graph Pad Prism version 5 (GraphPad software Inc, San Diego, CA, USA) was used for non-parametric correlation (Spearman) analysis. $P < 0.05$ was interpreted as indicating significant correlation.

Results

Table 2 summarizes the agreement between MGIT and the other two methods in determining MICs of each of the drugs, except isoniazid and dapsone, for the 10 MAP isolates. Isoniazid and dapsone MICs by all methods were greater than the highest concentration tested. MICs determined by MGIT and BACTEC methods showed 80–100% agreement at $\pm 1 \log_2$ dilution (i.e. one doubling dilution) for ciprofloxacin, levofloxacin, azithromycin, rifampicin, rifabutin and clofazimine. The MICs of azithromycin in un-alkalized (pH 6.7) BACTEC™ 12B radiometric medium were > 2 -fold higher than the MICs determined in MGIT™ ParaTB medium (data not shown). MICs of azithromycin in MGIT™ ParaTB medium (pH 6.8) correlated better with those in alkalized (pH 7.3) BACTEC™ 12B medium. Clarithromycin was tested at pH 6.8 in both broth media and showed 60% agreement at $\pm 1 \log_2$ dilution and 100% agreement at $\pm 2 \log_2$ dilutions. However, for this drug,

Table 2. Agreement in MIC determinations by MGIT in comparison with BACTEC and agar dilution methods for nine antimicrobials against 10 MAP strains

| Drug | Percentage agreement in MIC determination between methods | | | | | |
|------------------|---|-------------------------|--------------------------|------------------------|-------------------------|--------------------------|
| | MGIT and BACTEC | | | MGIT and agar dilution | | |
| | same dilution | $\pm 1 \log_2$ dilution | $\pm 2 \log_2$ dilutions | same dilution | $\pm 1 \log_2$ dilution | $\pm 2 \log_2$ dilutions |
| CIP | 70 | 100 | — | 70 | 90 | 100 |
| LVX | 60 | 100 | — | 40 | 90 | 100 |
| AZM ^a | 90 | 100 | — | 40 | 100 | — |
| CLR ^b | 20 | 60 | 100 | 70 | 90 | 100 |
| AMK ^c | ND | ND | ND | 10 | 60 | 100 |
| RIF | 60 | 90 | 100 | 10 | 60 | 80 |
| RFB | 20 | 80 | 100 | 30 | 70 | 100 |
| EMB | 40 | 70 | 100 | 0 | 50 | 90 |
| CLF ^c | 30 | 90 | 100 | 10 | 90 | 100 |

CIP, ciprofloxacin; LVX, levofloxacin; AZM, azithromycin; CLR, clarithromycin; AMK, amikacin; RIF, rifampicin; RFB, rifabutin; EMB, ethambutol; CLF, clofazimine; ND, not determined.

^aMICs at pH 6.8 in MGIT™ ParaTB medium and pH 7.3 in BACTEC™ 12B medium.

^bMICs at pH 6.8.

^cMICs in the absence of egg yolk.

there was better agreement between MGIT and agar dilution (70%, 90% and 100% at the same, ± 1 and ± 2 log₂ dilutions, respectively). MICs of ethambutol showed 70% and 100% agreement between MGIT and BACTEC methods at ± 1 and ± 2 log₂ dilutions, respectively. The MICs of ethambutol were higher by the BACTEC method for most strains. Non-parametric correlation analysis of MICs obtained by MGIT and BACTEC methods showed significant correlation ($P < 0.05$) for all 10 drugs compared (between 80% and 98% for 9 drugs and 73% for ethambutol).

Amikacin MICs determined in MGIT medium without egg yolk in comparison with those found by the agar dilution method showed 60% agreement at ± 1 log₂ dilution and 100% agreement at ± 2 log₂ dilutions; generally, slightly higher MICs were obtained for most strains by the agar dilution method. MICs found by MGIT and agar dilution methods showed 90%–100% agreement at ± 1 log₂ dilution for ciprofloxacin, levofloxacin, azithromycin, clarithromycin and clofazimine. MICs of rifampicin, ethambutol and rifabutin showed 80%, 90% and 100% agreement between the MGIT and agar dilution methods at ± 2 log₂ dilutions. The agar dilution method yielded higher MICs of ethambutol, compared with both broth culture methods.

The MGIT and agar dilution methods showed significant MIC correlation for all drugs (64%–93%), except ethambutol (52%).

MIC range, MIC₅₀ and MIC₉₀ values determined by the MGIT method were compared with those by the BACTEC and agar dilution methods (Table 3). MIC ranges of ciprofloxacin, levofloxacin, azithromycin, clarithromycin, rifabutin, clofazimine (by all three methods) and amikacin (tested by two methods only) were either the same or differed by only one doubling dilution. The presence of egg yolk in broth caused >4-fold higher MICs of clofazimine and amikacin in broth methods compared with the agar method (data not shown). All strains tested were resistant to isoniazid and dapsone at the highest concentrations tested (higher than the respective C_{max} values) by all three methods. The upper limits of the MIC range of ethambutol and rifampicin were >2 log₂ dilutions higher by agar dilution. There was good agreement between methods with respect to MIC₅₀ and MIC₉₀ values (minimum concentration of a drug that inhibited at least 50% and 90%, respectively, of the strains tested) for all drugs except ethambutol. The MIC₉₀ of ethambutol was four times higher by the agar dilution as compared with the MGIT method. MGIT-derived MICs of all the drugs for *M. avium* strains 101 and 104 are shown in Table 4.

Table 3. Summary of MICs of 11 drugs for 10 MAP strains determined by three methods

| Drug | MIC (mg/L) range | | | MIC ₅₀ and MIC ₉₀ by three methods | | | | | |
|------------------|------------------|-----------|---------------|--|-------------------|-------------------|-------------------|-------------------|-------------------|
| | MGIT | BACTEC | agar dilution | MGIT | | BACTEC | | agar dilution | |
| | | | | MIC ₅₀ | MIC ₉₀ | MIC ₅₀ | MIC ₉₀ | MIC ₅₀ | MIC ₉₀ |
| CIP | 0.25–8 | 0.25–4 | 0.25–8 | 0.5 | 8 | 0.5 | 4 | 0.5 | 8 |
| LVX | 0.25–16 | 0.5–16 | 0.25–32 | 1 | 16 | 1 | 8 | 1 | 32 |
| AZM ^a | 0.5–8 | 0.5–8 | 0.5–8 | 2 | 4 | 2 | 4 | 1 | 8 |
| CLR ^b | 0.13–1 | 0.25–4 | 0.13–1 | 0.13 | 1 | 0.5 | 1 | 0.13 | 1 |
| AMK ^c | 0.78–6.25 | ND | 1.56–12.5 | 1.56 | 3.13 | ND | ND | 3.13 | 6.25 |
| RIF | 0.09–3 | 0.19–3 | 0.19–12 | 0.37 | 3 | 0.37 | 3 | 0.75 | 6 |
| RFB | 0.13–2 | 0.25–2 | 0.13–4 | 0.25 | 1 | 0.5 | 2 | 0.13 | 1 |
| EMB | 1.25–5 | 1.25–20 | 5–20 | 5 | 5 | 5 | 10 | 10 | 20 |
| CLF ^c | 0.16–1.25 | 0.16–1.25 | 0.16–0.63 | 0.62 | 1.25 | 0.16 | 0.63 | 0.16 | 0.63 |
| DPS | >5 | >5 | >5 | | | | | | |
| INH | >8 | >8 | >8 | | | | | | |

CIP, ciprofloxacin; LVX, levofloxacin; AZM, azithromycin; CLR, clarithromycin; AMK, amikacin; RIF, rifampicin; RFB, rifabutin; EMB, ethambutol; CLF, clofazimine; DPS, dapsone; INH, isoniazid; ND, not determined.

^aMICs at pH 6.8 in MGIT™ ParaTB medium and pH 7.3 in BACTEC™ 12B medium.

^bMICs at pH 6.8.

^cMICs in the absence of egg yolk.

Table 4. MICs of various drugs for *M. avium* strains 101 and 104, as determined by the MGIT method

| Strain | MIC (mg/L) | | | | | | | | | | |
|--------|------------|-----|-----|------|------|--------|--------|-----|-------|-----|-----|
| | CIP | LVX | AZM | CLR | AMK | RIF | RFB | EMB | CLF | DPS | INH |
| MAC101 | ≤1 | 1 | 2 | ≤0.5 | 1.56 | ≤0.375 | ≤0.125 | 5 | 0.625 | >5 | 2 |
| MAC104 | ≤1 | 1 | 8 | ≤0.5 | 6.25 | ≤0.375 | ≤0.125 | 5 | 1.25 | >5 | 2 |

CIP, ciprofloxacin; LVX, levofloxacin; AZM, azithromycin; CLR, clarithromycin; AMK, amikacin; RIF, rifampicin; RFB, rifabutin; EMB, ethambutol; CLF, clofazimine; DPS, dapsone; INH, isoniazid.

Drug susceptibility testing of *M. paratuberculosis*

Table 5. Tentative classification^a of MAP strains by the MGIT drug susceptibility method and comparison with that of the BACTEC and agar dilution methods

| Drug | MGIT and BACTEC methods | | | | MGIT and agar dilution methods | | | | agreement (%) | | | | |
|------------------|-------------------------|--------|--------|--------------|--------------------------------|---------|--------|--------|---------------|--------|---------|---------|---------|
| | both S | both I | both R | S and I | R and I | S and R | both S | both I | | both R | S and I | R and I | S and R |
| AZM ^b | 10 | | | | | | 10 | | | | | | 100 |
| CLR ^b | 10 | | | | | | 10 | | | | | | 100 |
| CIP ^c | 7 | | 3 | | | | 7 | | 3 | | | | 100 |
| AMK ^c | | | | not compared | | | 5 | | | 4 | 1 | | 50 |
| RIF ^c | 5 | 3 | | 2 | | | 5 | 2 | | 2 | 1 | | 70 |
| RFB ^c | | 5 | 1 | 2 | 2 | | 2 | 2 | | 4 | 2 | | 40 |
| EMB ^c | 2 | 3 | | 1 | 4 | | | | | 1 | 7 | 2 | 0 |
| CLF ^c | 1 | | 3 | 3 | 2 | 1 | 40 | 1 | | 3 | 3 | 2 | 40 |

S, susceptible; I, intermediate; R, resistant; AZM, azithromycin; CLR, clarithromycin; CIP, ciprofloxacin; AMK, amikacin; RIF, rifampicin; RFB, rifabutin; EMB, ethambutol; CLF, clofazimine.

^aBased on interpretive criteria for MAC recommended by: ^bthe CLSI,²⁹ and ^cHeifets.³²

Currently there are no criteria for drug susceptibility interpretation specific for MAP. However, for MAC organisms, the CLSI defines clinically significant resistance to two macrolides, azithromycin and clarithromycin, as MICs >256 mg/L and >32 mg/L, respectively, using the BACTECTM 12B medium at pH 6.8.²⁹ For other drugs that are active against MAC, there are thresholds for MIC interpretation determined in 7H12 broth.³² To evaluate the ability of the MGIT method to designate MAP strain drug susceptibility, the 10 MAP strains tested were classified as susceptible, intermediate or resistant to eight drugs based on the two aforementioned criteria. Drug susceptibility classification by the MGIT method showed 70%–100% agreement with the BACTEC and agar dilution methods for ciprofloxacin, azithromycin, clarithromycin and rifampicin (Table 5). Except for clofazimine and ethambutol, disagreement between the MGIT and the other two methods was observed whenever the other methods classified a strain as susceptible versus intermediate or resistant versus intermediate. For ethambutol, two strains, UCF3 and UCF8, were classified as susceptible by the MGIT method but resistant by agar dilution. One strain (Linda) was classified as resistant to clofazimine by the MGIT method but susceptible by the other two methods. There are no cut-offs proposed for three drugs tested in this study against MAC: levofloxacin, isoniazid and dapsone. For three MAP strains, the MICs of levofloxacin were at or above its C_{max} ,³³ while for all 10 strains the MICs were higher than the respective C_{max} for isoniazid and dapsone^{34,35} by all three methods. Based on the same criteria, the MGIT-derived MICs classified the two MAC strains 101 and 104 as susceptible to ciprofloxacin, azithromycin, clarithromycin, rifampicin and rifabutin. Strain 101 was found susceptible to amikacin, while strain 104 showed intermediate amikacin susceptibility. Both strains showed intermediate susceptibility to ethambutol, but resistance to clofazimine and dapsone.

For MAP, the time required to determine MICs by the MGIT method was 7–10 days, while the BACTEC method required 10–12 days, depending upon the MAP strain being tested. However, azithromycin testing in BACTECTM 12B medium at pH 7.2 required slightly longer (12–14 days), due to a slower

MAP growth rate at the more alkaline pH. MIC determinations for MAP by the agar dilution method required 4–5 weeks.

Discussion

The fully automated, non-radiometric MGIT 960 system in conjunction with the MGITTM ParaTB medium allows rapid and sensitive recovery of MAP from clinical specimens. The present study shows that the system can also be reliably used for drug susceptibility testing of MAP strains. MICs of all drugs compared between MGIT and BACTEC methods showed 60%–100% agreement at single doubling dilution or 100% agreement at two doubling dilution differences. MICs by MGIT and agar dilution methods agreed 60%–100% at single doubling dilution or 100% at two doubling dilution differences for all drugs except rifampicin and ethambutol. The higher MICs of rifampicin determined by agar dilution could be due to decreased stability of the drug in agar and the extended incubation time required to obtain results, as reported in other studies.³⁶ The MICs of ethambutol in Middlebrook 7H12 broth are known to be lower than in 7H11 agar plates and the difference is more pronounced for *M. avium* than *M. tuberculosis*.³⁷ The present study shows that the MIC₉₀ of ethambutol for MAP is 2-fold higher by the BACTEC and 4-fold higher by the agar dilution method. However, Piersimoni *et al.*³⁸ showed 2-fold lower MICs of ethambutol for MAC in BACTECTM 12B medium compared with MGIT. This discrepancy could be due to differences in media composition as the MGITTM ParaTB medium is specifically enriched for growth of MAP. Moreover, observations with clofazimine and amikacin indicated that egg yolk in broth media results in ≥4-fold higher MICs of these drugs for MAP (data not shown). Decreased activity of clofazimine in the presence of egg yolk in the medium was observed in a prior drug stability study as well.²⁷ However, a similar effect of egg yolk on amikacin was not observed in that study, probably due to the test strain (*Escherichia coli*) used for amikacin.

Since the few published studies on drug susceptibility of MAP report data on a limited number of strains, few drugs and a

variety of methods, comparison of studies is difficult. However, results for ciprofloxacin, ethambutol, rifampicin and dapsona in the present study are comparable to those of Zanetti *et al.*,³⁹ who studied 12 MAP strains, of both human and animal origin, using the MGIT system. The discrepancies for clarithromycin and rifabutin (lower MICs found in the present study) could be due to changes in the broth medium employed as well as differences in the strains used. MICs of clarithromycin obtained in the present study correlate well with those of a study by Rastogi *et al.*²⁰ using the BACTEC method and five MAP isolates; minimal correlation for fluoroquinolones and rifampicin MICs was seen between the two studies.

A provisional antibiotic response classification of the 10 MAP strains as susceptible, intermediate or resistant to some of the drugs based on published interpretative criteria available for MAC showed 100% (macrolides and ciprofloxacin) and 80% (rifampicin) agreement between MGIT and the other two methods. For other drugs, the lesser agreement (40%–70%) observed between MGIT and other methods results mostly from classification of strains in the ‘intermediate’ category. Major discordance was observed for clofazimine against one strain, which was classified resistant by MGIT but susceptible by the other two methods. This discrepancy was probably due to the closer (one doubling dilution difference) MIC cut-offs used for clofazimine. It should be noted that clofazimine MICs determined by MGIT showed 90% agreement with those found by both the BACTEC and agar dilution methods at $\pm 1 \log_2$ dilution and 100% agreement at $\pm 2 \log_2$ dilutions. In comparison with reported susceptibility/resistance profiles for *M. avium*,³² MAP are more resistant than *M. avium* to isoniazid, but more susceptible to amikacin and ciprofloxacin. Similar to *M. avium*, all MAP isolates tested were found susceptible to the macrolides azithromycin and clarithromycin. In conclusion, the MGIT 960TM system with MGITTM ParaTB medium can be used for rapid and reliable drug susceptibility testing of MAP.

Acknowledgements

We thank Ms Kelly Anklam for technical assistance provided on this project.

Funding

This work was funded in part by the Broad Medical Research Program of The Broad Foundation.

Transparency declarations

M. T. C. is a paid consultant to BD Diagnostic Systems. All other authors: none to declare.

References

1. Abubakar I, Myhill D, Aliyu SH *et al.* Detection of *Mycobacterium avium* subspecies *paratuberculosis* from patients with Crohn's disease using nucleic acid-based techniques: a systematic review and meta-analysis. *Inflamm Bowel Dis* 2008; **14**: 401–10.
2. Behr MA, Kapur V. The evidence for *Mycobacterium paratuberculosis* in Crohn's disease. *Curr Opin Gastroenterol* 2008; **24**: 17–21.
3. Feller M, Huwiler K, Stephan R *et al.* *Mycobacterium avium* subspecies *paratuberculosis* and Crohn's disease: a systematic review and meta-analysis. *Lancet Infect Dis* 2007; **7**: 607–13.
4. Lowe AM, Yansouni CP, Behr MA. Causality and gastrointestinal infections: Koch, Hill, and Crohn's. *Lancet Infect Dis* 2008; **8**: 720–6.
5. Scanu AM, Bull TJ, Cannas S *et al.* *Mycobacterium avium* subspecies *paratuberculosis* infection in cases of irritable bowel syndrome and comparison with Crohn's disease and Johne's disease: common neural and immune pathogenicities. *J Clin Microbiol* 2007; **45**: 3883–90.
6. Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease. *Am J Gastroenterol* 2000; **95**: 725–9.
7. Williams SL, Harris NB, Barletta RG. Development of a firefly luciferase-based assay for determining antimicrobial susceptibility of *Mycobacterium avium* subsp. *paratuberculosis*. *J Clin Microbiol* 1999; **37**: 304–9.
8. Borody TJ, Bilkey S, Wettstein AR *et al.* Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars. *Dig Liver Dis* 2007; **39**: 438–44.
9. Goodgame RW, Kimball K, Akram S *et al.* Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. *Aliment Pharmacol Ther* 2001; **15**: 1861–6.
10. Inoue S, Nakase H, Matsuura M *et al.* Open label trial of clarithromycin therapy in Japanese patients with Crohn's disease. *J Gastroenterol Hepatol* 2007; **22**: 984–8.
11. Leiper K, Martin K, Ellis A *et al.* Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. *Aliment Pharmacol Ther* 2008; **27**: 1233–9.
12. Leiper K, Morris AI, Rhodes JM. Open label trial of oral clarithromycin in active Crohn's disease. *Aliment Pharmacol Ther* 2000; **14**: 801–6.
13. Selby W, Pavli P, Crotty B *et al.* Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. *Gastroenterology* 2007; **132**: 2313–9.
14. Shafraan I, Kugler L, El-Zaatari FA *et al.* Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. *Dig Liver Dis* 2002; **34**: 22–8.
15. Behr MA, Hanley J. Antimycobacterial therapy for Crohn's disease: a reanalysis. *Lancet Infect Dis* 2008; **8**: 344.
16. Kuenstner JT. The Australian antibiotic trial in Crohn's disease: alternative conclusions from the same study. *Gastroenterology* 2007; **133**: 1742–3; author reply 1745–6.
17. Greenstein RJ, Su L, Haroutunian V *et al.* On the action of methotrexate and 6-mercaptopurine on *M. avium* subspecies *paratuberculosis*. *PLoS ONE* 2007; **2**: e161.
18. Greenstein RJ, Su L, Juste RA *et al.* On the action of cyclosporine A, rapamycin and tacrolimus on *M. avium* including subspecies *paratuberculosis*. *PLoS ONE* 2008; **3**: e2496.
19. Parrish NM, Ko CG, Dick JD *et al.* Growth, Congo Red agar colony morphotypes and antibiotic susceptibility testing of *Mycobacterium avium* subspecies *paratuberculosis*. *Clin Med Res* 2004; **2**: 107–14.
20. Rastogi N, Goh KS, Labrousse V. Activity of clarithromycin compared with those of other drugs against *Mycobacterium paratuberculosis* and further enhancement of its extracellular and intracellular activities by ethambutol. *Antimicrob Agents Chemother* 1992; **36**: 2843–6.
21. Siddiqi SH, Heifets LB, Cynamon MH *et al.* Rapid broth macrodilution method for determination of MICs for *Mycobacterium avium* isolates. *J Clin Microbiol* 1993; **31**: 2332–8.

Drug susceptibility testing of *M. paratuberculosis*

22. Grant IR, Kirk RB, Hitchings E *et al.* Comparative evaluation of the MGIT and BACTEC culture systems for the recovery of *Mycobacterium avium* subsp. *paratuberculosis* from milk. *J Appl Microbiol* 2003; **95**: 196–201.
23. Somoskövi A, Ködmön C, Lantos A *et al.* Comparison of recoveries of *Mycobacterium tuberculosis* using the automated BACTEC MGIT 960 system, the BACTEC 460 TB system, and Löwenstein-Jensen medium. *J Clin Microbiol* 2000; **38**: 2395–7.
24. Garrigó M, Aragón LM, Alcaide F *et al.* Multicenter laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of *Mycobacterium tuberculosis*. *J Clin Microbiol* 2007; **45**: 1766–70.
25. Rüsç-Gerdes S, Pfyffer GE, Casal M *et al.* Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of *Mycobacterium tuberculosis* to classical second-line drugs and newer antimicrobials. *J Clin Microbiol* 2006; **44**: 688–92.
26. Shin SJ, Han JH, Manning EJ *et al.* Rapid and reliable method for quantification of *Mycobacterium paratuberculosis* by use of the BACTEC MGIT 960 system. *J Clin Microbiol* 2007; **45**: 1941–8.
27. Krishnan MY, Manning EJ, Collins MT. Stability of antibacterial agents in MGIT™ ParaTB medium. *Int J Antimicrob Agents* 2009; **33**: 186–7.
28. Shin SJ, Collins MT. Thiopurine drugs azathioprine and 6-mercaptopurine inhibit *Mycobacterium paratuberculosis* growth in vitro. *Antimicrob Agents Chemother* 2008; **52**: 418–26.
29. National Committee for Clinical Laboratory Standards. *Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes: Approved Standard M24-A*. NCCLS, Wayne, PA, USA, 2003.
30. Lambrecht RS, Carriere JF, Collins MT. A model for analyzing growth kinetics of a slowly growing *Mycobacterium* sp. *Appl Environ Microbiol* 1988; **54**: 910–6.
31. Inderleid CB, Salfinger M. Antimicrobial agents and susceptibility tests: mycobacteria. In: Murray PR, Baron EJ, Pfaller MA eds. *Manual of Clinical Microbiology*. Washington, DC: ASM Press, 1995; 1385–404.
32. Heifets L. Susceptibility testing of *Mycobacterium avium* complex isolates. *Antimicrob Agents Chemother* 1996; **40**: 1759–67.
33. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. *Chest* 2001; **119**: 1114–22.
34. Peloquin CA, Jaresko GS, Yong CL *et al.* Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. *Antimicrob Agents Chemother* 1997; **41**: 2670–9.
35. Pieters FA, Zuidema J. The pharmacokinetics of dapsone after oral administration to healthy volunteers. *Br J Clin Pharmacol* 1986; **22**: 491–4.
36. Bemer-Melchior P, Bryskier A, Drugeon HB. Comparison of the in vitro activities of rifapentine and rifampicin against *Mycobacterium tuberculosis* complex. *J Antimicrob Chemother* 2000; **46**: 571–6.
37. Heifets LB, Iseman MD, Lindholm-Levy PJ. Ethambutol MICs and MBCs for *Mycobacterium avium* complex and *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 1986; **30**: 927–32.
38. Piersimoni C, Nista D, Bornigia S *et al.* Evaluation of a new method for rapid drug susceptibility testing of *Mycobacterium avium* complex isolates by using the mycobacteria growth indicator tube. *J Clin Microbiol* 1998; **36**: 64–7.
39. Zanetti S, Molicotti P, Cannas S *et al.* 'In vitro' activities of antimycobacterial agents against *Mycobacterium avium* subsp. *paratuberculosis* linked to Crohn's disease and paratuberculosis. *Ann Clin Microbiol Antimicrob* 2006; **5**: 27.